Protein Core Facility
BPRC is often a collaborative partner to evaluate new vaccine candidates. Yet, we also have our own pipeline for vaccine development. The scientists at BPRC have many years of experience in vaccine development.
PfAMA1, the protein vaccine against the malaria parasite Plasmodium falciparum was developed at BPRC's protein core facility. AMA1 plays a key role in the entry of the parasite into red blood cells and therefore AMA1 is a good vaccine candidate. After optimizing vaccine design, expression and purification procedures the vaccine was used in a proof of concept study in monkeys. After an extended vaccination procedure PfAMA1 provided partial protection against the malaria disease. However, in people the vaccine did not suffice. Combining PfAMA1 with another vaccine candidate may overcome this in the future.TO TOP ^ < BACK << HOME
Virus like particles vaccine platform
Virus like particles (VLPs) are molecules that resemble viruses but VLPs do not contain genetic material, and thus non-infectious. VLPs are capable of activating the immune system and generate a virus specific immune response. Therefore VLPs are sometimes used as a vaccine. The vaccine that is currently used to protect women from cervical cancer caused by HPV is also based in virus like particle technique.
In line with this, BPRC’s protein core facility designed VLPs for Usutu virus and Zika virus. Both vaccine candidates are in early stage of development. The envelope proteins were produced by recombinant techniques, purified and biochemically prepared to generate VLP’s. In vitro experiments showed that both Zika as well as Usutu VLPs bind Zika and Usutu specific antibodies, respectively. Both VLPs will be further evaluated for immunogenicity and their potential as human vaccines.TO TOP ^ < BACK << HOME